3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial

Dean J. Kereiakes,Stephen G. Ellis,Christopher Metzger,Ronald P. Caputo,David G. Rizik,Paul S. Teirstein, Marc R. Litt,Annapoorna Kini,Ameer Kabour,Steven O. Marx,Jeffrey J. Popma,Robert McGreevy,Zhen Zhang,Charles Simonton,Gregg W. Stone

Journal of the American College of Cardiology（2017）

引用 209|浏览0

暂无评分

摘要

In the ABSORB III trial, 3-year adverse event rates were higher with BVS than EES, particularly TVMI and device thrombosis. Longer-term clinical follow-up is required to determine whether bioresorption of the polymeric scaffold will influence patient prognosis. (ABSORB III Randomized Controlled Trial [RCT] [ABSORB-III]; NCT01751906).

查看译文

关键词

bioresorbable scaffold,prognosis,randomized trial,stent

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要